Herein, we report a real-world case of acute hepatitis induced by crizotinib in an ALK-rearranged positive NSCLC patient, in whom the treatment shift for a second-generation ALK-inhibitor after the event recovery. The gene discussed is ALK; the disease is non-small cell lung carcinoma.